Explore the vast range of titles available.

背景:近年来, 糖尿病领域的技术进步使糖尿病患者及其所处环境的管理、预后和生活质量发生了革命性的变化。本研究的目的是评估MiniMed TM 780G闭环系统对既往接受过持续皮下胰岛素输注泵和间歇性血糖监测治疗的儿童和青少年人群的影响。 方法:收集28例年龄6~17岁的1型糖尿病患者资料, 随访6个月。我们纳入了血糖测定和生活质量变量, 以及主要照顾者的生活质量。在引入闭环系统后的不同时间点(48小时、7天、14天、21天、1个月、3个月、6个月)评估了代谢控制变量。 结果:在新系统自动化后的48小时内, 血糖在70~180 mg/dL范围内的时间从基线时的59.44%增加到74.29%, 并且这种改善在其他切点也是如此, 180~ 250mg/dL的高血糖时间(基线时24.44%降低到48小时的18.96%)和>250 mg/dL的高血糖时间(基线时11.71%降低到48小时时3.82%)也是如此。 结论:我们的研究表明, 从系统自动化后的最初48小时开始, 血糖控制范围内的时间和高血糖持续时间均有所改善, 并维持至6个月。

Abstract Background In recent years, technological advances in the field of diabetes have revolutionized the management, prognosis, and quality of life of diabetes patients and their environment. The aim of our study was to evaluate the impact of implementing the MiniMed 780G closed‐loop system in a pediatric and adolescent population previously treated with a continuous subcutaneous insulin infusion pump and intermittent glucose monitoring. Methods Data were collected from 28 patients with type 1 diabetes aged 6 to 17 years, with a follow‐up of 6 months. We included both glucometric and quality of life variables, as well as quality of life in primary caregivers. Metabolic control variables were assessed at baseline (before system change) and at different cutoff points after initiation of the closed‐loop system (48 hours, 7 days, 14 days, 21 days, 1 month, 3 months, 6 months). Results Time in range 70–180 mg/dL increased from 59.44% at baseline to 74.29% in the first 48 hours after automation of the new system, and this improvement was maintained at the other cutoff points, as was time in hyperglycemia 180–250 mg/dL (24.44% at baseline to 18.96% at 48 hours) and >250 mg/dL (11.71% at baseline to 3.82% at 48 hours). Conclusions Our study showed an improvement in time in range and in all time spent in hyperglycemia from the first 48 hours after the automation of the system, which was maintained at 6 months.

Background/Objectives: Type 1 diabetes mellitus (T1D) is the most common metabolic disorder in children, with significant physical and emotional impacts. Achieving optimal glucometric control is challenging due to the complex management and limitations of insulin therapy. Advances in pharmacology and technology, including continuous glucose monitoring (CGM) systems, offer new options for diabetes management. We developed Andiacare, an open-source platform for macro/micro-management of diabetes and analyzed its application in a pediatric T1D cohort to evaluate glucometric control patterns. Methods: A retrospective cohort study was conducted in a pediatric population (<18 years old) in Andalusia, Spain. Patients treated with Multiple Daily Injections of Insulin (MDI) and FreeStyle Libre 2 System (Abbott, Spain) were included. The patient data were analyzed using the Andiacare platform, which categorizes patients based on the Advanced Technologies and Treatments for Diabetes (ATTD) panel’s targets for glucometric control. Results: The study included 2215 patients from 18 pediatric hospitals. The Andiacare platform categorized patients into four groups based on glucometric control parameters, enabling patient stratification based on their glucometric control. Only 25.8% of the cohort achieved the recommended Time in Range (TIR), and 9.5% of the patients achieved all target parameters of glucometric control. Age is a determinant factor in adherence and achievement of set goals. Conclusions: This study offers insights into glucometric control in a large pediatric population with T1D in Andalusia. Few patients achieved the recommended glucometric control targets, highlighting the need for improved management strategies. The use of digital platforms such as Andiacare might contribute to facilitating the management of large pediatric cohorts. New algorithms integrating glucometric and non-glucometric parameters are required for improved individual and cohort categorization to optimize therapeutic interventions.